Explore Intellia Therapeutics, Inc.'s outlook after Phase 3 trial concerns. See how FDA decisions may impact CRISPR therapy ...
A new paper from the University of Kansas overturns the idea that a "risk gene" carried by millions of people worldwide ...
A new paper from the University of Kansas overturns the idea that a "risk gene" carried by millions of people worldwide ...
ToolGen and GenEditBio have previously collaborated on GEB-200 and completed a proof-of-concept study in non-human primates. As they advance GEB-200 through clinical trials, the companies said they ...
Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology Pursues a once-and-done treatment paradigm for diseases with ...
The immune system plays a crucial role in fighting tumors and metastases. Consequently, it is decisive to conduct cancer research in mouse models with an immune system that is as natural as possible – ...
JUPITER, Fla. and DUBLIN, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing ...
Mycobacterium abscessus has emerged as a critical global public health threat, particularly among immunocompromised individuals (van Dorn, 2017). As a rapidly growing nontuberculous mycobacterium (NTM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback